Compare IDEXX Laboratories, Inc. (IDXX) vs Personalis Inc. Common Stock (PSNL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Personalis Inc. Common Stock — how do they compare? IDEXX Laboratories, Inc. trades at $535.5 (market cap $41.68B), while Personalis Inc. Common Stock trades at $15.75 (market cap $1.70B). The key difference: IDEXX Laboratories, Inc. is far larger — about 24.5× Personalis Inc. Common Stock's market cap, and Personalis Inc. Common Stock is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 47 Days and Personalis Inc. Common Stock for 0 Days on average.
| IDXX | PSNL | |
|---|---|---|
Market Cap | $41.68B | $1.70B |
Volume | 824,427 | 3,262,398 |
Sector | Health | Health |
52-Week High | $766.68 | $18.38 |
52-Week Low | $504.70 | $5.04 |
Typical Hold Time | 47 Days | 0 Days |
Enterprise Value | $42.58B | $1.52B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Personalis Inc. Common Stock
Personalis Inc. is a cancer genomics company that provides tumor- and blood-based DNA and RNA sequencing tests, including its NeXT Personal liquid biopsy test for cancer monitoring.
Read more on PSNL →
